Adding penpulimab to chemotherapy can improve progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma, data suggest.

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC).

Stage IV cancer is often called metastatic cancer and means the tumor has grown further still and that the cancer has spread to many more lymph nodes and other parts of the body—often including ...

for two indications treating nasopharyngeal carcinoma (NPC). The drug is now indicated in combination with chemotherapy as a first-line treatment for adult patients with recurrent or metastatic ...

Results of a meta-analysis suggest that enfortumab vedotin plus pembrolizumab is more effective than chemotherapy as first-line treatment for patients with metastatic urothelial cancer ...

Lymph nodes (LNs) are the staging grounds for anti-tumor immunity, therefore their high susceptibility to metastatic colonization is a paradox. Previous studies have suggested that extrinsic ...

Experts developed consensus recommendations through the modified Delphi process for metastatic prostate cancer management during the 2024 US Prostate Cancer Conference. A multidisciplinary panel of ...

Olivia Williams, known for her roles in ‘Dune: Prophecy’ and ‘The Crown’, recently opened up about her ongoing battle with metastatic pancreatic cancer. The condition is also known as ...

HER2-positive metastatic breast cancer is an aggressive disease driven by overexpression or amplification of HER2, affecting 15-20% of patients with metastatic breast cancer. While HER2-targeted ...

“This is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic breast cancer patient population compared to the current first-line standard of ...

Full results from the Phase III ASCENT-04/KEYNOTE-D19 study demonstrated statistically significant and clinically meaningful survival benefits in patients with previously untreated, PD-L1-positive ...